The abbreviation of lupus, systemic red weeds (SLE) is a complex self-immunised disease that can weigh on multiple systems and dirty organs all over the body, severely affecting the quality of life of patients and endangering lives. An in-depth examination of the mechanisms for its occurrence and the current state of its treatment is crucial to overcoming the pandemic.
The lupus outbreak mechanism involves the interplay of genetic, environmental, immune and other factors. Genetic factors play an important role in lupus outbreaks, and studies have found that multiple genetic locations are associated with lupus susceptibility. However, genetic factors alone are not sufficient to cause disease, and environmental factors such as UV exposure, viral infections, certain drugs, etc. can induce sores. Incentived by these factors, the immune system of the organism has been disrupted, and normal immune cells have lost their tolerance to their own organization, producing a large number of their own antibodies, such as anti-nuclei. These self-antibodies, combined with their own antigens, form immunosuppressants, are deposited in small vascular walls in the skin, kidneys, joints, etc., and activate the remedial system, causing inflammatory reactions, which in turn leads to tissue damage and organ dysfunction. For example, the deposition of immunochemical compounds in the kidneys can cause lupus renal inflammation in the form of protein urine, blood urine, etc. and can develop into kidney failure in serious cases.
At present, the treatment of lupus is mainly drug-oriented and is aimed at controlling disease activity, reducing relapses and protecting dirty body functions. Sugar cortex hormones are one of the most common drugs used to treat lupus, and have a strong anti-inflammation and immunosuppression effect, which can quickly alleviate the symptoms of fever, rashes and joint pains. However, long-term high levels of use can lead to many adverse effects, such as osteoporosis, increased risk of infection and increased blood sugar. Immunosuppressants such as cyclophosphos-amide, mescomphenol, etc., are also widely used for lupus treatment, and they reduce the generation of their own antibody by inhibiting the growth and functioning of immunosupulation cells, which plays an important role in controlling the progress of the disease and preventing damage to organs. However, there are also some side effects of immunosuppressants, such as bone marrow inhibition and damage to liver and kidney function.
In recent years, the emergence of biological agents has created new hope for lupus treatment. The first biological agent to be approved for SLE treatment is the Baleywood Single Resistance, which reduces B-cell activation and self-antibody generation by inhibiting B lymphocytes. It improves patients ‘ condition and reduces the risk of relapse, and is more secure and resistant than traditional immunosuppressants. In addition, there are new biological agents that are in the development or clinical trial phase, such as drugs for interferopaths, which are expected to provide more treatment options for lupus patients.
Despite some progress in treatment, lupus remains an incurable disease, often requiring long-term or even life-long medication and close monitoring of adverse drug reactions and changes in conditions. The current treatment, which focuses heavily on the control of symptoms and delays in the progress of the disease, continues to face enormous challenges in restoring the body ‘ s own immunity and achieving a complete cure for the disease. In the future, as research on lupus mechanisms deepens, it is expected that more accurate, efficient and safe treatments will be developed to bring new light to lupus patients.
